Dataset Information


Beneficial effects of RAF inhibitor in mutant BRAF splice variant-expressing melanoma.

ABSTRACT: Resistance to RAF inhibitors such as vemurafenib and dabrafenib is a major clinical problem in the treatment of melanoma. Patients with mutant BRAF melanoma that progress on RAF inhibitors have limited treatment options, and drug removal from resistant tumors may elicit multiple effects. A frequent mechanism of resistance to RAF inhibitors is caused by expression of mutant BRAF splice variants. RAF inhibitor-resistant cell lines, generated in vivo, were tested as to whether or not mutant BRAF splice variants confer a fitness advantage in the presence of RAF inhibitor. Critically, cells expressing distinct mutant BRAF splice variants grow more efficiently in vitro and in vivo in the presence of the vemurafenib analog, PLX4720, compared with in the absence of inhibitor. PLX4720-treated BRAF splice variant-expressing cells exhibited levels of phospho-extracellular signal-regulated kinase (ERK)1/2 comparable to untreated parental cells. In addition, a reduction in phospho-ERK1/2 levels following treatment with the MEK inhibitor, trametinib (GSK1120212) phenocopied the fitness benefit provided by PLX4720. These data indicate that mutant BRAF splice variant-expressing melanoma cells are benefited by defined concentrations of RAF inhibitors.This study provides evidence that RAF inhibitor-resistant melanoma cells benefit from continued therapy.

SUBMITTER: Hartsough EJ 

PROVIDER: S-EPMC4020954 | BioStudies | 2014-01-01

REPOSITORIES: biostudies

Similar Datasets

2014-01-01 | S-EPMC3988223 | BioStudies
2013-01-01 | S-EPMC3695051 | BioStudies
2015-01-01 | S-EPMC4458462 | BioStudies
2012-01-01 | S-EPMC3308191 | BioStudies
2018-01-01 | S-EPMC5752590 | BioStudies
1000-01-01 | S-EPMC3625308 | BioStudies
2012-01-01 | S-EPMC3627494 | BioStudies
2013-01-01 | S-EPMC3563727 | BioStudies
1000-01-01 | S-EPMC4674359 | BioStudies
2014-01-01 | S-EPMC4850735 | BioStudies